NZ702666A - A method of weight reduction - Google Patents
A method of weight reductionInfo
- Publication number
- NZ702666A NZ702666A NZ702666A NZ70266613A NZ702666A NZ 702666 A NZ702666 A NZ 702666A NZ 702666 A NZ702666 A NZ 702666A NZ 70266613 A NZ70266613 A NZ 70266613A NZ 702666 A NZ702666 A NZ 702666A
- Authority
- NZ
- New Zealand
- Prior art keywords
- present disclosure
- weight reduction
- reduction
- methazolamide
- hyperglycaemia
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000013585 weight reducing agent Substances 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000014101 glucose homeostasis Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 abstract 1
- 229960004083 methazolamide Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651335P | 2012-05-24 | 2012-05-24 | |
| PCT/AU2013/000259 WO2013173858A1 (en) | 2012-05-24 | 2013-03-15 | A method of weight reduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ702666A true NZ702666A (en) | 2016-08-26 |
Family
ID=49622926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ702666A NZ702666A (en) | 2012-05-24 | 2013-03-15 | A method of weight reduction |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150174108A1 (enExample) |
| EP (1) | EP2854806A4 (enExample) |
| JP (1) | JP6438389B2 (enExample) |
| KR (1) | KR20150023404A (enExample) |
| CN (1) | CN104582701B (enExample) |
| AU (1) | AU2013202981B2 (enExample) |
| BR (1) | BR112014029302A2 (enExample) |
| CA (1) | CA2874512A1 (enExample) |
| CO (1) | CO7160083A2 (enExample) |
| HK (1) | HK1209041A1 (enExample) |
| MX (1) | MX2014014316A (enExample) |
| NZ (1) | NZ702666A (enExample) |
| RU (1) | RU2664442C2 (enExample) |
| SG (1) | SG11201407786XA (enExample) |
| WO (1) | WO2013173858A1 (enExample) |
| ZA (1) | ZA201408703B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2106260T3 (enExample) | 2007-01-25 | 2018-05-05 | ||
| CN109498623A (zh) * | 2012-05-24 | 2019-03-22 | 纳亚代谢有限公司 | 改善肝功能的方法 |
| US10039752B2 (en) * | 2016-07-21 | 2018-08-07 | Cipla Limited | Methazolamide for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2783241A (en) * | 1957-02-26 | S-acylimino-x-substituted-az-i | ||
| JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
| US6946243B2 (en) * | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
| US20020055458A1 (en) * | 2000-08-11 | 2002-05-09 | Einar Stefansson | Method for the prevention and treatment of retinopathy |
| RU2356247C2 (ru) * | 2003-03-18 | 2009-05-27 | Новартис Аг | Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор |
| MXPA05011557A (es) * | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| EP1680131A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED INDOLE-O-GLUCOSIDES |
| WO2007114948A2 (en) * | 2006-04-04 | 2007-10-11 | The Brigham And Women's Hospital, Inc. | Methods and compositions for inhibiting cell death |
| NO2106260T3 (enExample) * | 2007-01-25 | 2018-05-05 | ||
| WO2011002011A1 (ja) * | 2009-07-01 | 2011-01-06 | キッセイ薬品工業株式会社 | Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬 |
| ES2706913T3 (es) * | 2010-06-25 | 2019-04-01 | Univ Aston | Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas |
| EP2583965B1 (en) * | 2010-07-15 | 2017-01-25 | Takeda Pharmaceutical Company Limited | Heterocyclic ring compound |
| CN109498623A (zh) * | 2012-05-24 | 2019-03-22 | 纳亚代谢有限公司 | 改善肝功能的方法 |
-
2013
- 2013-03-15 HK HK15109728.3A patent/HK1209041A1/xx unknown
- 2013-03-15 EP EP13794519.2A patent/EP2854806A4/en not_active Withdrawn
- 2013-03-15 SG SG11201407786XA patent/SG11201407786XA/en unknown
- 2013-03-15 MX MX2014014316A patent/MX2014014316A/es unknown
- 2013-03-15 BR BR112014029302A patent/BR112014029302A2/pt not_active Application Discontinuation
- 2013-03-15 US US14/403,495 patent/US20150174108A1/en not_active Abandoned
- 2013-03-15 CN CN201380033658.6A patent/CN104582701B/zh not_active Expired - Fee Related
- 2013-03-15 AU AU2013202981A patent/AU2013202981B2/en not_active Ceased
- 2013-03-15 NZ NZ702666A patent/NZ702666A/en not_active IP Right Cessation
- 2013-03-15 KR KR20147035499A patent/KR20150023404A/ko not_active Withdrawn
- 2013-03-15 CA CA2874512A patent/CA2874512A1/en not_active Abandoned
- 2013-03-15 RU RU2014150946A patent/RU2664442C2/ru not_active IP Right Cessation
- 2013-03-15 JP JP2015512967A patent/JP6438389B2/ja not_active Expired - Fee Related
- 2013-03-15 WO PCT/AU2013/000259 patent/WO2013173858A1/en not_active Ceased
-
2014
- 2014-11-26 ZA ZA2014/08703A patent/ZA201408703B/en unknown
- 2014-12-19 CO CO14279766A patent/CO7160083A2/es unknown
-
2018
- 2018-02-09 US US15/892,989 patent/US20180333398A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014014316A (es) | 2015-07-06 |
| RU2664442C2 (ru) | 2018-08-17 |
| WO2013173858A1 (en) | 2013-11-28 |
| AU2013202981B2 (en) | 2014-11-13 |
| ZA201408703B (en) | 2018-07-25 |
| US20180333398A1 (en) | 2018-11-22 |
| JP6438389B2 (ja) | 2018-12-12 |
| CN104582701A (zh) | 2015-04-29 |
| CN104582701B (zh) | 2018-01-16 |
| KR20150023404A (ko) | 2015-03-05 |
| BR112014029302A2 (pt) | 2017-06-27 |
| RU2014150946A (ru) | 2016-07-10 |
| SG11201407786XA (en) | 2015-03-30 |
| EP2854806A1 (en) | 2015-04-08 |
| CA2874512A1 (en) | 2013-11-28 |
| HK1209041A1 (en) | 2016-03-24 |
| JP2015520759A (ja) | 2015-07-23 |
| EP2854806A4 (en) | 2015-11-18 |
| CO7160083A2 (es) | 2015-01-15 |
| US20150174108A1 (en) | 2015-06-25 |
| AU2013202981A1 (en) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201503110B (en) | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | |
| WO2013169864A3 (en) | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE | |
| MX2019000586A (es) | Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd). | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| PH12013500919B1 (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
| WO2012062925A3 (en) | Compounds and methods for treating pain | |
| WO2010018217A3 (en) | Purin derivatives for use in the treatment of fab-related diseases | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| WO2010080756A3 (en) | Harmine derivatives for reducing body weight | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| IN2014MN02089A (enExample) | ||
| EA201370230A1 (ru) | Новые ингибиторы rock | |
| EA201290603A1 (ru) | Способ лечения | |
| HK1198811A1 (en) | A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent | |
| MX347620B (es) | Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica. | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| MX357071B (es) | Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes. | |
| EP2106260A4 (en) | INSULIN SENSITIZERS AND TREATMENT PROCEDURES THEREWITH | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| NZ713295A (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
| NZ702666A (en) | A method of weight reduction | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| NZ624714A (en) | Methods for treating gout in patient subpopulations | |
| MX358072B (es) | Composiciones tópicas que comprenden diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que involucran un aumento del dolor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2018 BY CPA GLOBAL Effective date: 20170127 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2019 BY CPA GLOBAL Effective date: 20180201 |
|
| ASS | Change of ownership |
Owner name: NAIA METABOLIC, INC., C/O NAIA LIMITED, US Effective date: 20181029 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2020 BY CPA GLOBAL Effective date: 20190201 |
|
| LAPS | Patent lapsed |